Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
May cause major or fatal bleeding; monitor INR regularly. Drugs, dietary changes, and other factors affect INR levels achieved with therapy. Instruct patients about prevention measures to minimize risk of bleeding and to report signs/symptoms of bleeding.
Vitamin K-dependent coagulation factor inhibitor
Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE), and thromboembolic complications associated with atrial fibrillation (A-fib) and/or cardiac valve replacement. To reduce risk of death, recurrent myocardial infarction (MI), and thromboembolic events, such as stroke or systemic embolization after MI.
Including DVT and PE:Target INR: 2.5 (INR Range, 2-3) for all treatment durations
Duration of Therapy:DVT/PE Secondary to Transient Risk Factor: 3 monthsUnprovoked DVT/PE: At least 3 months; evaluate risk-benefit ratio of long-term treatment after 3 months of therapy2 Episodes of Unprovoked DVT/PE: Long-term treatment recommended
Target INR: 2.5 (INR Range, 2-3)
Duration of Therapy:Persistent/Paroxysmal A-Fib and High Risk of Stroke: Long-term treatment recommendedPersistent/Paroxysmal A-Fib and Intermediate Risk of Ischemic Stroke: Long-term treatment recommendedA-Fib and Mitral Stenosis: Long-term treatment recommendedA-Fib and Prosthetic Heart Valves: Long-term treatment recommended; target INR may be increased and ASA added depending on valve type and position, and on patient factors
Bileaflet Mechanical Valve/Medtronic Hall Tilting Disk Valve in the Aortic Position in Sinus Rhythm and w/o Left Atrial Enlargement:Target INR: 2.5 (INR Range, 2-3)
Tilting Disk Valves and Bileaflet Mechanical Valves in the Mitral Position: Target INR: 3 (INR Range, 2.5-3.5)
Caged Ball or Caged Disk Valves: Target INR: 3 (INR Range, 2.5-3.5)
Bioprosthetic Valve in the Mitral Position: Target INR: 2.5 (INR Range, 2-3) for the first 3 months after valve insertion. If additional risk factors for thromboembolism present, target INR 2.5 (INR Range, 2-3)
High Risk Patients w/ MI:Treat w/ combined moderate-intensity (INR Range, 2.0-3.0) warfarin plus low-dose ASA (≤100 mg/day) for at least 3 months after MI
Unknown Etiology:Use a moderate dose regimen (INR Range, 2-3)
Expected Maint Daily Doses Based on CYP2C9 and VKORC1 Genotypes:VKORC1-GG:CYP2C9 *1/*1: 5-7 mgCYP2C9 *1/*2: 5-7 mgCYP2C9 *1/*3: 3-4 mgCYP2C9 *2/*2: 3-4 mg CYP2C9 *2/*3: 3-4 mg CYP2C9 *3/*3: 0.5-2 mg
VKORC1-AG:CYP2C9 *1/*1: 5-7 mg CYP2C9 *1/*2: 3-4 mg CYP2C9 *1/*3: 3-4 mg CYP2C9 *2/*2: 3-4 mg CYP2C9 *2/*3: 0.5-2 mg CYP2C9 *3/*3: 0.5-2 mg
VKORC1-AA:CYP2C9 *1/*1: 3-4 mg CYP2C9 *1/*2: 3-4 mg CYP2C9 *1/*3: 0.5-2 mg CYP2C9 *2/*2: 0.5-2 mg CYP2C9 *2/*3: 0.5-2 mg CYP2C9 *3/*3: 0.5-2 mg
CYP2C9 *1/*3, *2/*2, *2/*3, and *3/*3: May require more prolonged time (>2-4 weeks) to achieve max INR effect
If CYP2C9 and VKORC1 Genotypes are Unknown: Initial: 2-5mg qdMaint: 2-10mg qd
Mitral Stenosis/Valvular Disease Associated w/ A-Fib:Use a moderate dose regimen (INR Range, 2-3)
From Heparin:Conversion may begin concomitantly w/ heparin therapy or may be delayed 3-6 days Continue full dose heparin therapy and overlap warfarin therapy for 4-5 days; D/C heparin once warfarin has produced the desired therapeutic response as determined by INR
Patients receiving both heparin and warfarin should have INR monitoring at least:5 hrs after the last IV bolus heparin dose, or4 hrs after cessation of continuous IV heparin infusion, or24 hrs after the last SQ heparin inj
Warfarin may increase the aPTT test, even in the absence of heparin; severe elevation (>50 sec) in aPTT w/ INR in desired range has been identified as an indication of increased risk of postoperative hemorrhage
From Other Anticoagulants:Consult the labeling of other anticoagulants for conversion instructions
ElderlyAND/OR Debilitated: Consider lower initial and maint doses
Other Important ModificationsAsian Patients: Consider lower initial and maint dosesTreatment During Dentistry or Surgery: Some procedures may necessitate an interruption or change in dose
(Coumadin, Jantoven) Oral or (Coumadin) IV routeCoumadinIV dose is the same as oral doseIV:Reconstitute vial w/ 2.7mL of SWFI; resulting yield is 2.5mL of a 2mg/mL solAfter reconstitution, administer as a slow bolus inj into a peripheral vein over 1-2 min
Inj: (Coumadin) 5mg; Tab: (Coumadin, Jantoven) 1mg*, 2mg*, 2.5mg*, 3mg*, 4mg*, 5mg*, 6mg*, 7.5mg*, 10mg* *scored
Pregnancy, except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism. Hemorrhagic tendencies or blood dyscrasias. Recent or contemplated surgery of the CNS, eye, or traumatic surgery resulting in large open surfaces. Bleeding tendencies associated with active ulceration or overt bleeding of GI/genitourinary/respiratory tract, CNS hemorrhage, cerebral aneurysms, dissecting aorta, pericarditis and pericardial effusions, or bacterial endocarditis. Threatened abortion, eclampsia, and preeclampsia. Unsupervised patients with conditions associated with potential high level of noncompliance. Spinal puncture and other diagnostic/therapeutic procedures with potential for uncontrollable bleeding. Major regional, lumbar block anesthesia. Malignant HTN.
Has no direct effect on established thrombus, nor does it reverse ischemic tissue damage. Some dental/surgical procedures may need interruption or change in the dose; determine INR immediately prior to procedure. Has a narrow therapeutic range (index) and its action may be affected by endogenous factors, other drugs, and dietary vitamin K; perform periodic INR monitoring. Risk of necrosis and/or gangrene of skin and other tissues; d/c if necrosis occurs and consider alternative therapy. May enhance the release of atheromatous plaque emboli, and systemic atheroemboli and cholesterol microemboli may occur. D/C if distinct syndrome resulting from microemboli to the feet ("purple toes syndrome") occurs. Do not use as initial therapy with heparin-induced thrombocytopenia (HIT) and with heparin-induced thrombocytopenia with thrombosis syndrome (HITTS); limb ischemia, necrosis, and gangrene reported when heparin was discontinued and warfarin started or continued. Can cause fetal harm in pregnant women. Increased risks of therapy in patients with hepatic impairment, infectious diseases/disturbances of intestinal flora, indwelling catheter, severe/moderate HTN, deficiency in protein C-mediated anticoagulant response, polycythemia vera, vasculitis, diabetes, and those undergoing eye surgery. Caution in elderly and hepatic impairment.
Hemorrhage, necrosis of the skin and other tissues, systemic atheroemboli, cholesterol microemboli, hypersensitivity/allergic reactions, vasculitis, hepatitis, elevated liver enzymes, N/V, diarrhea, rash, dermatitis, tracheal/tracheobronchial calcifications, chills.
May increase effect (increase INR) with CYP2C9, 1A2, and/or 3A4 inhibitors. May decrease effect (decrease INR) with CYP2C9, 1A2, and/or 3A4 inducers. Increased risk of bleeding with anticoagulants (argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin), antiplatelet agents (ASA, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine), NSAIDs (celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac), serotonin reuptake inhibitors (eg, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone). Changes in INR reported with antibiotics or antifungals; closely monitor INR when starting or stopping any antibiotics or antifungals. Use caution with botanical (herbal) products. May potentiate anticoagulant effects with some botanicals (eg, garlic, Ginkgo biloba). May decrease effects with some botanicals (eg, coenzyme Q10, St. John's wort, ginseng). Some botanicals and foods can interact through CYP450 interactions (eg, echinacea, grapefruit juice, ginkgo, goldenseal, St. John's wort). Cholestatic hepatitis has been associated with coadministration of warfarin and ticlopidine.
Category D (with mechanical heart valves) or Category X (for other pregnant populations), caution in nursing.
Vitamin K-dependent coagulation factor inhibitor; thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide.
Absorption: (PO) Complete; Tmax=4 hrs. Distribution: Vd=0.14L/kg; plasma protein binding (99%); crosses placenta. Metabolism: Hepatic via CYP2C9, 2C19, 2C8, 2C18, 1A2, 3A4; hydroxylation (major), reduction. Elimination: Urine (≤92%, metabolites); T1/2=1 week.
Assess for risk factors for bleeding (eg, age ≥65 yrs, history of highly variable INR, GI bleeding, HTN, cerebrovascular disease, malignancy, anemia, trauma, renal impairment, certain genetic factors), factors affecting INR (eg, diarrhea, hepatic disorders, poor nutritional state, steatorrhea, vitamin K deficiency, increased vitamin K intake, hereditary warfarin resistance), pregnancy/nursing status, other conditions where treatment is contraindicated or cautioned, and drug-drug/drug-disease interactions. Assess INR. Obtain platelet counts in patients with HIT or HITTS.
Monitor for signs/symptoms of bleeding, necrosis/gangrene of skin and other tissues, systemic atheroemboli, cholesterol microemboli, "purple toes syndrome," and other adverse reactions. Perform periodic INR testing.
Instruct to inform physician if patient falls often as this may increase risk for complications. Counsel to maintain strict adherence to dosing regimen. Advise not to start or stop other medications, including salicylates (eg, ASA, topical analgesics), OTC drugs, or herbal medications, except on advice of physician. Instruct to inform physician if pregnancy is suspected (to discuss pregnancy planning) or if considering breastfeeding. Counsel to avoid any activity or sport that may result in traumatic injury. Instruct that regular PT tests and visits to physician are required during therapy. Advise patient to carry ID card stating drug is being taken. Instruct to eat a normal, balanced diet to maintain consistent intake of vitamin K and to avoid drastic changes in diet, such as eating large amounts of leafy, green vegetables. Advise to take ud. Advise to immediately report unusual bleeding or symptoms or any serious illness, such as severe diarrhea, infection, or fever. Inform that anticoagulant effects may persist for about 2 to 5 days after discontinuation.
Tab: (Coumadin) 15-30°C (59-86°F). (Jantoven) 20-25°C (68-77°F); excursions permitted 15-30°C (59-86°F). Protect from light and moisture. Inj: (Coumadin) 15-30°C (59-86°F). Protect from light. Use reconstituted sol within 4 hrs. Do not refrigerate. Discard any unused sol.